DAFNA Capital Management LLC grew its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 11.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 377,695 shares of the biopharmaceutical company’s stock after purchasing an additional 38,081 shares during the period. DAFNA Capital Management LLC owned approximately 2.10% of Xenon Pharmaceuticals worth $1,190,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Endurant Capital Management LP bought a new stake in shares of Xenon Pharmaceuticals during the 1st quarter valued at about $1,363,000. Sabby Management LLC bought a new stake in shares of Xenon Pharmaceuticals during the 1st quarter valued at about $1,186,000. Renaissance Technologies LLC boosted its stake in shares of Xenon Pharmaceuticals by 90.1% during the 1st quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock valued at $868,000 after purchasing an additional 102,890 shares in the last quarter. K2 Principal Fund L.P. boosted its stake in shares of Xenon Pharmaceuticals by 40.6% during the 2nd quarter. K2 Principal Fund L.P. now owns 164,510 shares of the biopharmaceutical company’s stock valued at $518,000 after purchasing an additional 47,535 shares in the last quarter. Finally, KCG Holdings Inc. bought a new stake in shares of Xenon Pharmaceuticals during the 1st quarter valued at about $122,000. 55.30% of the stock is currently owned by hedge funds and other institutional investors.

In other Xenon Pharmaceuticals news, CFO Ian Mortimer bought 15,000 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were bought at an average cost of $2.88 per share, for a total transaction of $43,200.00. Following the acquisition, the chief financial officer now directly owns 6,000 shares in the company, valued at $17,280. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Bvf Partners L. P/Il bought 18,858 shares of the company’s stock in a transaction on Tuesday, August 15th. The shares were acquired at an average price of $2.41 per share, for a total transaction of $45,447.78. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 210,739 shares of company stock worth $568,975. 9.40% of the stock is owned by company insiders.

A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday. Jefferies Group LLC set a $5.00 price target on shares of Xenon Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 4th. Finally, Canaccord Genuity reissued a “buy” rating and set a $5.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, June 27th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $10.63.

Shares of Xenon Pharmaceuticals Inc. (XENE) traded up 7.69% on Thursday, reaching $3.15. 50,130 shares of the company were exchanged. The company’s market capitalization is $56.69 million. The company’s 50-day moving average is $3.03 and its 200-day moving average is $3.68. Xenon Pharmaceuticals Inc. has a 52 week low of $2.25 and a 52 week high of $9.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.03). Xenon Pharmaceuticals had a negative return on equity of 47.53% and a negative net margin of 3,489.63%. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.38 million. On average, equities analysts expect that Xenon Pharmaceuticals Inc. will post ($0.97) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/dafna-capital-management-llc-increases-stake-in-xenon-pharmaceuticals-inc-xene/1610248.html.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.